Eli Samaha
CIK 1877589 · last filed 2026-10-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TBPH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
FLOOR 65
NEW YORK, NY 10007
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| STGW | Director | 8,187,543 | $8.71 | $71.27M | $19.18M | 22 | 2026-10-02 |
| Theravance Biopharma, Inc. (TBPH) Delisted | 10%+ Owner | 9,167,489 | $17.03 | $156.12M | $15.00M | 4 | 2026-07-08 |
| SYNOVUS FINANCIAL CORP (SNV) Delisted | 10%+ Owner | 1,293,259 | $50.39 | $65.17M | -$3.79M | 10 | 2024-06-11 |
| PFSWEB INC (PFSW) Delisted | 10%+ Owner | 2,633,189 | $7.49 | $19.72M | $2.10M | 5 | 2022-12-30 |
Recent Filings · Page 3 of 5
41 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-04 | SYNOVUS FINANCIAL CORP (SNV) Delisted | Sell (S) | −219,963 | -$5.52M | EDGAR |
| 2024-05-03 | Theravance Biopharma, Inc. (TBPH) Delisted | Buy (P) | +1,499,124 | $13.12M | EDGAR |
| 2023-10-24 | SYNOVUS FINANCIAL CORP (SNV) Delisted | Buy (P) | +560 | $12.0K | EDGAR |
| 2023-10-16 | SYNOVUS FINANCIAL CORP (SNV) Delisted | Buy (P) | +4,514 | $97.1K | EDGAR |
| 2023-10-11 | SYNOVUS FINANCIAL CORP (SNV) Delisted | Buy (P) | +2,910 | $62.2K | EDGAR |
| 2023-10-04 | SYNOVUS FINANCIAL CORP (SNV) Delisted | Buy (P) | +3,466 | $73.8K | EDGAR |
| 2023-09-28 | SYNOVUS FINANCIAL CORP (SNV) Delisted | Buy (P) | +12,196 | $259.8K | EDGAR |
| 2023-09-26 | SYNOVUS FINANCIAL CORP (SNV) Delisted | Buy (P) | +26,222 | $558.5K | EDGAR |
| 2023-09-21 | SYNOVUS FINANCIAL CORP (SNV) Delisted | Buy (P) | +243,014 | $5.20M | EDGAR |
| 2023-06-16 | STGW | Grant (A) | +18,940 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.